Hasan Md Lemon, Lee Ju Ro, Rahaman Khandoker Asiqur, Yang Dae Hyeok, Joung Yoon Ki
Center for Biomaterials, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Hwarangno 14-gil 5, Seongbuk-gu, Seoul, 02792, Republic of Korea.
Division of Bio-Medical Science & Technology, University of Science and Technology (UST), 113 Gwahangno, Yuseong-gu, Daejeon, 34113, Republic of Korea.
Bioact Mater. 2024 Sep 3;42:207-225. doi: 10.1016/j.bioactmat.2024.08.026. eCollection 2024 Dec.
Modulating inflammatory cells in an implantation site leads to severe complications and still unsolved challenges for blood-contacting medical devices. Inspired by the role of galectin-1 (Gal-1) in selective functions on multiple cells and immunomodulatory processes, we prepared a biologically target-specific surface coated with the lipid bilayer containing Gal-1 (Gal-1-SLB) and investigate the proof of the biological effects. First, lipoamido-dPEG-acid was deposited on a gold-coated substrate to form a self-assembled monolayer and then conjugated dioleoylphosphatidylethanolamine (DOPE) onto that to produce a lower leaflet of the supported lipid bilayer (SLB) before fusing membrane-derived vesicles extracted from B16-F10 cells. The Gal-1-SLB showed the expected anti-fouling activity by revealing the resistance to protein adsorption and bacterial adhesion. studies showed that the Gal-1-SLB can promote endothelial function and inhibit smooth muscle cell proliferation. Moreover, Gal-1- SLB presents potential function for endothelial cell migration and angiogenic activities. macrophage culture studies showed that the Gal-1-SLB attenuated the LPS-induced inflammation and the production of macrophage-secreted inflammatory cytokines. Finally, the implanted Gal-1-SLB reduced the infiltration of immune cells at the tissue-implant interface and increased markers for M2 polarization and blood vessel formation . This straightforward surface coating with Gal-1 can be a useful strategy for modulating the vascular and immune cells around a blood-contacting device.
调节植入部位的炎症细胞会导致严重并发症，对于与血液接触的医疗设备来说，这仍然是尚未解决的挑战。受半乳糖凝集素-1（Gal-1）在多种细胞的选择性功能和免疫调节过程中所起作用的启发，我们制备了一种涂有含Gal-1脂质双层的生物靶向特异性表面（Gal-1-SLB），并研究其生物学效应的证据。首先，将硫辛酸-二聚乙二醇-酸沉积在镀金基板上形成自组装单层，然后在其上共轭二油酰磷脂酰乙醇胺（DOPE）以产生支撑脂质双层（SLB）的下层小叶，之后融合从B16-F10细胞中提取的膜衍生囊泡。Gal-1-SLB通过显示出对蛋白质吸附和细菌粘附的抗性，表现出预期的抗污活性。研究表明，Gal-1-SLB可以促进内皮功能并抑制平滑肌细胞增殖。此外，Gal-1-SLB在内皮细胞迁移和血管生成活动方面具有潜在功能。巨噬细胞培养研究表明，Gal-1-SLB减弱了LPS诱导的炎症以及巨噬细胞分泌的炎性细胞因子的产生。最后，植入的Gal-1-SLB减少了组织-植入物界面处免疫细胞的浸润，并增加了M2极化和血管形成的标志物。这种用Gal-1进行的直接表面涂层可能是调节血液接触装置周围血管和免疫细胞的有用策略。
